References
- Handley D. The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists. J Allergy Clin Immunol 1999; 104:S69–S76.
- Volcheck GW, Kelkar P, Bartemes KR, Gleich GJ, Kita H. Effects of (R)- and (S)-isomers of beta-adrenergic agonists on eosinophil response to Interleukin-5. Clin Exp Allergy 2005; 35:1341–1346.
- Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003; 143:731–736.
- Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005; 21:415–419.
- Qureshi F, Zaritsky A, Welch C, Meadows T, Burke BL. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005; 46:29–36.
- Andrews T, McGintee E, Mittal MK, Tyler L, Chew A, Zhang X, Pawlowski N, Zorc JJ. High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. J Pediatr 2009; 155:205–210.
- Gawchik S, Saccar C, Noonan M, Reasner D, DeGraw S. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999; 103:615–621.
- Berger W, Milgrom H, Skoner D, Tripp K, Parsey M, Maumgartner R. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. Curr Med Res Opin 2006; 22(6):1217–1226.
- Lotvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca P, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108:726–731.
- Handley D, Tinkelman D, Noonan M, Rollins T, Snider M, Caron J. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000; 37(4):319–327.
- Pleskow W, Nelson H, Schaefer K, Claus R, Roach J. Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004; 25:429–436.
- Ralston M, Euwema M, Knecht K, Ziolkowski T, Coakley T, Cline S. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med 2005; 29(1):29–35.
- Skoner D, Greos L, Kim K, Roach J, Parsey M, Baumgartner R. Evaluation of the safety and efficacy of levalbuterol in 2–5-year-old patients with asthma. Pediatr Pulm 2005; 40:477–486.
- Schreck D, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med 2005; 23:842–847.
- Milgrom H, Skoner D, Bensch G, Kim K, Claus R, Baumgartner R. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001; 108:938–945
- Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998; 339(15):1030–1035.